Teluca

Teluca is a clinical-stage biotechnology company specializing in the development of targeted radiopharmaceuticals for the treatment of hard-to-treat cancers. The company's lead program, TL-001, is a radiolabeled amino acid analog targeting the L-type amino acid transporter 1 (LAT1), currently being evaluated in Phase 1/2 clinical trials for glioblastoma multiforme. Teluca leverages its expertise in radiochemistry and oncology to create precision medicines that deliver therapeutic radiation directly to tumor cells while sparing healthy tissue. The company is headquartered in New Jersey and was founded by industry veterans with extensive experience in the radiopharmaceutical sector.